Rinvoq Tablet, Extended Release
Product Images NDC 0074-2310

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 12 technical images submitted to the FDA as part of the official labeling for Rinvoq (NDC 0074-2310). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Abbvie Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Rinvoq 01

Rinvoq 01
FDA Label Image

Rinvoq 02

Rinvoq 02
FDA Label Image

Rinvoq 03

Rinvoq 03
FDA Label Image

Rinvoq 04

Rinvoq 04
FDA Label Image

Rinvoq 05

Rinvoq 05
The text is describing a response rate percentage of 100 and displaying a graph with weeks on the X-axis and i Placebo + TCS, RINVOQ 16 mg 0D + TCS, and RINVOQ 30 mg 0D + TCS on the Y-axis. The graph has data points at V2, 4, 6, 8, 10, 12, 14, and 16 weeks. However, the text does not provide any additional information to fully understand the context of the graph or the response rate.*
FDA Label Image

Rinvoq 06

Rinvoq 06
FDA Label Image

Rinvoq 07

Rinvoq 07
FDA Label Image

Rinvoq 08

Rinvoq 08
FDA Label Image

Rinvoq 09

Rinvoq 09
FDA Label Image

Rinvoq 0a

Rinvoq 0a
FDA Label Image

Rinvoq 0b

Rinvoq 0b
FDA Label Image

Rinvoq 0c

Rinvoq 0c

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.